1048973-47-2
基本信息
苯甲酸 (2Z)-2-(1-己基-1,2-二氢-2-氧代-3H-吲哚-3-亚基)肼
MDA19
MDA-19
N'-(1-Hexyl-2-oxoindolin-3-ylidene)benzohydrazide
(Z)-N'-(1-hexyl-2-oxoindolin-3-ylidene)benzohydrazide
N-[(Z)-(1-Hexyl-2-oxo-indolin-3-ylidene)aMino]benzaMide
N'-[(3Z)-1-Hexyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide
Benzoic acid (2Z)-2-(1-hexyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene)hydrazide
MDA 19 (Z)-N'-(1-hexyl-2-oxoindolin-3-ylidene)benzohydrazide
物理化学性质
| 密度 | 1.16±0.1 g/cm3 (20 ºC 760 Torr) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMF: 20 mg/ml; DMSO: 10 mg/ml; Ethanol: 3 mg/ml; Methanol: 1 mg/ml |
| 酸度系数(pKa) | 10.45±0.20(Predicted) |
| 形态 | 结晶固体 |
| 颜色 | Light yellow to yellow |
苯甲酸 (2Z)-2-(1-己基-1,2-二氢-2-氧代-3H-吲哚-3-亚基)肼价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-15451R | 苯甲酸 (2Z)-2-(1-己基-1,2-二氢-2-氧代-3H-吲哚-3-亚基)肼 MDA 19 (Standard) | 1048973-47-2 | 5 mg | 2000元 |
| 2026/09/15 | HY-15451 | 苯甲酸 (2Z)-2-(1-己基-1,2-二氢-2-氧代-3H-吲哚-3-亚基)肼 MDA 19 | 1048973-47-2 | 5mg | 880元 |
| 2026/09/15 | HY-15451R | 苯甲酸 (2Z)-2-(1-己基-1,2-二氢-2-氧代-3H-吲哚-3-亚基)肼 MDA 19 (Standard) | 1048973-47-2 | 10 mg | 3200元 |
常见问题列表
MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 +/- 2.1 vs 1130 +/- 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3',5'-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays.
MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.